LOS ANGELES, CA / ACCESS Newswire / August 19, 2025 / ClaimNotify.org, a new online tool and educational hub for all things unclaimed assets, launched today to help Californians easily navigate the complex world of abandoned assets. With a mission to become the trusted national resource, the platform empowers residents to recover funds and assets that rightfully belong to them.
Unclaimed assets- ranging from forgotten bank accounts and uncashed checks to insurance benefits and safe deposit box contents- are currently valued at over $2.5 billion in Los Angeles County and $600 million in San Diego County, according to recent public notices. Until now, finding and reclaiming these funds has been a confusing and time-consuming process.
The launch comes at a pivotal moment: on September 4, 2025, new California code changes- driven by the passage of SB 822, which expands the state’s Unclaimed Property Law to include digital financial assets- will make it easier for residents to submit claims online. ClaimNotify.org will offer up-to-the-minute guidance on these changes, ensuring no eligible Californian misses their opportunity to reclaim what’s theirs.
ClaimNotify.org streamlines the journey, offering:
A Centralized Resource for Californians: One place to access news, updates, and verified links for unclaimed asset searches, starting with California and expanding to other states.
Educational Tools: Easy-to-follow guides explaining what unclaimed assets are, how they get lost, and how residents can submit claims.
Breaking Updates: Timely alerts on new policies, large asset disclosures, and deadlines for filing claims.
Step-by-Step Support: Clear instructions to help users submit claims directly, without costly third-party services.
“Unclaimed assets can be life-changing, but most people don’t even realize they exist- let alone how to recover them,” said a ClaimNotify.org spokesperson. “Our goal is to be the go-to source for accurate, accessible, and timely information, so Californians can claim what’s theirs without unnecessary stress or confusion.”
Claim Notify plans to expand its coverage to include news and resources from multiple states, helping Americans nationwide access the billions in unclaimed property sitting in government coffers.
To view the resources and learn more, visit: Claimnotify.org
About ClaimNotify.org ClaimNotify.org is a public information portal dedicated to helping individuals navigate the often-confusing process of recovering unclaimed property. By consolidating updates, official resources, and step-by-step guides, ClaimNotify.org empowers people to reclaim their money and property with confidence. For more information, visit: ClaimNotify.org
CHARLOTTE, NC / ACCESS Newswire / August 19, 2025 / Most Sunseeker Tech products, including the X7 Series of state-of-the-art robotic mowers, can now be purchased online as a part of the new partnership between Sunseeker Tech and Lowe’s. This partnership marks a significant step in expanding Sunseeker’s reach to more homeowners in the United States. It offers innovative solutions with its advanced lawn care machines.
“At Sunseeker, robotic lawn care is the norm, not the exception. The collaboration with Lowe’s will enable us to target more homeowners than ever before, giving them the ease, accuracy, and sustainability,” said the CEO.
Putting Smart Lawn Care in More Lawns
With the collaboration between Lowe’s and Sunseeker, the company would turn a new leaf in its quest to popularize robotic mowing as an option among housekeepers. Lowe’s is the most recognized online shopping platform in home improvement in America.
It offers the best medium to reach the tech-savvy segment of consumers eager to find sustainable and efficient form of maintaining their property. This will allow customers in Charlotte and beyond to buy robotic mowers. This ensure professional-quality results with minimum human interaction.
Features of Sunseeker X7 Series
Among the product line, X7 Series is a fully autonomous robot lawn mower designed to provide unique lawn care experience, with highly advanced AI technology, RTK (Real-Time Kinematic) navigation and high-grade engineering.
It is unique due to the following features:
Adaptive AI Mowing Patterns: The mower learns and can adapt to growth of the grass, weather and obstacles providing smooth and consistent cutting
RTK-level Accuracy: Operates at sub-centimeter campus-wide accuracy without the use of perimeter wires. It can reduce cost on an installation and enhance dependability
Smart Collision Sensing: Automatically senses pets, children, and garden decor and goes around them unhindered
All-Weather Performance: The construction is designed to work in any kind of weather with rain sensors and IPX durability rating
The electric, less noisy motor of the X7 does not only limit environmental interference but also promotes silent work. It is a vehicle-friendly in the neighborhoods. With a companion mobile app, homeowners can view, schedule, and control their mower remotely from anyplace, welcoming it to their smart home system.
High-End, Low Pressure
The mission of Sunseeker is not just a grass cutting machine but about giving back time to people. The CEO said that the target was to assist homeowners in reclaiming their weekends. You will never have to worry about your lawn with Sunseeker. You can rest in knowing that you have one less thing to worry about because your lawn is well taken care of.
Whether on tightly trimmed urban gardens or expansive suburban gardens, the X7 is able to adjust to all set-ups. It can move over hills, rugged land, and different types of grasses easily. That is why it is good both in residential areas, Charlotte neighborhood, and golf resort spaces.
Making Lawn Care Futuristic
Robotic mowing has a positive impact on the world. Not only does it make life easier, but also helps create a healthier planet. When homeowners upgrade their gas mowers to battery-operated ones such as the X7, they reduce noise pollution caused by emissions.
Its smart scheduling of the mower also ensures that whether it cuts the lawn more often or less, it is healthy without any extra energy. This increased enthusiasm among consumers on eco-friendly technology that can sustain the lifestyle without sacrificing performance.
More Smarter Lawn Care
Sunseeker expects to be an entirely incorporated player in the smart home ecosystem. The company’s vision is that its mowers will interact with other smart devices and adapt intelligently to the shifts in the environment. It is also to present hyper-personalized mowing formats to the yard. As the company continues to innovate, it will continue to add more products to its line. It seeks to address the requirements of all kinds of homeowners, whether of a small city plot or large estate.
Availability
TheLowe’s online store now offers the Sunseeker robotic mowers, such as the X7 Series which is the more advanced version of their product line. Customers will have access to product specifications, models to compare, and convenience of shipping and customer services offered by Lowe’s.
To know more about the products of Sunseeker, you can visit the site www.sunseekertech.com Follow the brand on social media to get acquainted with the latest news, user experience, and views:
Sunseeker Robotic Technology will ensure it is a pioneer in smart yard technology recreating the outdoor living experience with the ideal totality of current robotics, AI navigation engineering, and green engineering. Its premium X7 Series robotic mower is the benchmark of accuracy, adaptability, and convenience in a robot mower. This makes it more versatile to the homeowner that cares about performance and sustainability.
Coupled with the drive to undeniably innovate and make its customers happy, Sunseeker is constantly exploring ways to automate exterior maintenance. So, people spend less time maintaining their lawns and more time enjoying them.
Media Details: Website URL: sunseekertech.com Company Name: Sunseeker North America Email address: marketing.global@sunseekertech.com Address: 4330 Matthews Indian Trail Rd STE A Indian Trail, NC, USA 28079
The new relationship brings extensive experience to elevate client offerings and support future growth
PHILADELPHIA, PA / ACCESS Newswire / August 19, 2025 / Commonwealth M&A, LLC, a premier full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium sized businesses, today announced that Joe DiGiacomo has joined the team as a Senior Advisor and Managing Director. DiGiacomo will play a key role in company operations managing specific transactions, and will also offer counsel on other transactions, utilizing his 40+ years of experience to ensure deals close smoothly, companies get the valuation they deserve, and sellers are optimized to secure the best transition for their business.
A seasoned professional who is well-established in the lower middle market, DiGiacomo has a diverse background in investment banking, business valuation, accounting, and mergers and acquisitions. Most recently as the Founder and President of D5 Capital Advisors, a boutique lower middle market M&A advisory firm headquartered in the Lehigh Valley, as well as previous positions as the President and CFO of a $135 million multimodal transportation and logistics business, and Partner of a regional CPA firm.
“Our goals for Commonwealth M&A have been big from the start and bringing Joe on our team is going to supercharge our capabilities,” said Rick Calabrese, co-founder of Commonwealth M&A. “Having previously worked with Joe in my capacity as a transactional attorney, I know first hand the wealth of knowledge and experience he brings to the table. We are excited to add his expertise to our team to continue to bring our clients exceptional results, which is always our top priority.”
“When I was considering combining my practice with another firm, I knew I wanted to join a team that was talented and motivated. I had worked with Rick in the past and when I found out he had started his own firm, I immediately wanted to learn more. I met with him and Joe [Bergin] and the pieces just fell into place, their mindset and business approach is exactly what I was looking for,” commented Joe DiGiacomo. “This team knows what they’re doing and I really think that their energy and technical experience paired with my background is going to be a dynamic offering. I’m very excited about this new chapter and know there’s an extremely bright future ahead for Commonwealth M&A.”
In the last calendar year alone, Commonwealth M&A has closed more than $50M in transaction value for clients. Founders Rick Calabrese and Joe Bergin both offer unique expertise, Calabrese as a transactional attorney and CPA, and Bergin with a decade of corporate M&A experience at Johnson & Johnson. The team believes they can leverage DiGiacomo’s broad expertise to help lower middle market businesses find a deal that fits all of their needs.
About Commonwealth M&A, LLC Commonwealth M&A, LLC is a full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium-sized businesses. Commonwealth M&A offers a differentiated approach derived from the team’s diverse set of experiences. Our mission is to deliver personalized, high-quality service that exceeds expectations. Visit us at https://commonwealthmna.com/
SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the company’s ongoing clinical development program for crofelemerfor the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder. Members of Napo’s Scientific Advisory Board will join Napo and Jaguar representatives at the meeting.
“We’re very pleased that Napo has been granted a meeting with the FDA to discuss Napo’s development plans for crofelemer for MVID – a devastating pediatric disease characterized by severe malabsorption that requires life-sustaining parenteral support to meet the nutritional, fluid and electrolyte requirements of the child, and for which there no approved drug treatments,” said Pravin Chaturvedi, PhD, Napo’s and Jaguar’s Chief Scientific Officer and Chair of the Scientific Advisory Board. “A core Napo goal for this meeting is to obtain input from the FDA on the clinical program and potential expedited regulatory pathways for this rare orphan indication.”
As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, the initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) of a novel crofelemer powder formulation for oral solution in Abu Dhabi in the United Arab Emirates show that crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in the first participating MVID patient by up to 27%. An abstract describing the initial results of this trial has been accepted for presentation at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place November 5-8, 2025 in Chicago.
Jaguar, through Napo, is supporting the independent proof-of-concept IIT in pediatric intestinal failure (IF) patients at Sheikh Khalifa Medical City in Abu Dhabi, and is conducting the placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients with IF at sites in the U.S., European Union, and Middle East/North Africa regions under appropriate regulatory approvals in each of these geographies.
“Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval,” said Lisa Conte, Jaguar’s Founder and CEO.
Based on the initial findings from the IIT in Abu Dhabi, crofelemer’s paradigm-shifting mechanism of action has the potential to provide a novel therapeutic option to reduce parenteral support and associated complications in MVID patients.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that Napo personnel will meet with the FDA to discuss Napo’s development plans for crofelemer for MVID, statements regarding Jaguar’s expectation that an abstract describing the results of the investigator-initiated trial in Abu Dhabi will be presented at NASPGHAN 2025, Jaguar’s expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval, and Jaguar’s expectation that crofelemer’s paradigm-shifting mechanism of action has the potential to provide a novel therapeutic option to reduce parenteral support and associated complications in MVID patients. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025
MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the successful completion of the Single Ascending Dose (SAD) portion of its ongoing Phase 1 clinical trial evaluating oral Ketamir-2. The study, conducted at the Hadassah Clinical Research Center in Israel under the direction of Principal Investigator Prof. Yoseph Caraco, demonstrated a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed to date.
“Completion of the SAD portion with a favorable safety and tolerability profile is an important milestone in the clinical development of Ketamir-2,” said Prof. Yoseph Caraco, Principal Investigator of the Phase 1 study. “Importantly, no severe or clinically significant adverse effects have been observed to date, which supports continued progression into the Multiple Ascending Dose stage of the trial.”
Phase 1 Study Overview
The study- “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Centre Study of Single and Repeated Dosing of Ascending Doses, to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects“-is designed to establish the safety, tolerability, and pharmacokinetics of Ketamir-2 in healthy adult volunteers.
Design: Single-center, randomized, double-blind, placebo-controlled SAD/MAD with sentinel dosing and Safety Steering Committee (SSC) reviews between cohorts.
SAD completed: Four cohorts (single doses 50 mg to 600 mg); 32 participants treated (male and female).
Safety monitoring: Extensive central nervous system (CNS) safety assessments were performed using well-validated clinical research tools:
Columbia-Suicide Severity Rating Scale (C-SSRS) – screens for suicidal ideation or behavior, supporting early detection of potential mood or psychiatric changes.
Bowdle Visual Analogue Scale (VAS) – measures possible psychedelic or dissociative effects sometimes seen with ketamine and related compounds.
Ketamine Side Effect Tool (KSET) – tracks a broad range of known ketamine-related side effects over time, including sensory, cognitive, and mood changes. These tools provided multiple, complementary layers of safety evaluation to help detect even subtle CNS effects throughout the trial.
Status: To date, no severe or clinically significant adverse effects have been observed at any dose level in the SAD portion of the study.
While the study remains ongoing and blinded, it is worth noting that, across the pharmaceutical industry as a whole, approximately one-third of investigational drugs fail during Phase 1 due to safety concerns (Tufts Center for the Study of Drug Development). These interim observations provide encouraging context as MIRA advances Ketamir-2 through the next stage of clinical evaluation, consistent with the Company’s mission to prioritize safety in every step of development.
The Company is advancing to the Multiple Ascending Dose (MAD) portion, which will evaluate three cohorts receiving daily oral doses of 150 mg, 300 mg, or 600 mg for five consecutive days in up to 24 participants.
“The emerging human safety profile complements the preclinical data we’ve generated, which show Ketamir-2’s superior efficacy in multiple neuropathic pain models without triggering the hallmark CNS side effects of ketamine,” said Dr. Itzchak Angel, Chief Scientific Advisor of MIRA. “This combination of efficacy, safety, and oral delivery positions Ketamir-2 as a promising next-generation treatment for neuropathic pain and potentially other CNS disorders.“
Strategic & Commercial Potential
Ketamir-2 is a proprietary, orally bioavailable new molecular entity that selectively targets the NMDA receptor (PCP site) with low affinity and shows no significant off-target activity across a broad receptor panel. Preclinical studies have demonstrated superior performance versus ketamine, pregabalin, or gabapentin (depending on comparator and model) in gold-standard neuropathic pain models-without the dissociative effects associated with ketamine.
Neuropathic pain affects an estimated 36-51 million people in North America and represents a multi-billion-dollar market today, with long-term growth driven by diabetes prevalence, cancer survivorship, and aging-related nerve damage. MIRA intends to submit a Phase 2a clinical protocol in neuropathic pain by year-end 2025 and continue evaluating potential applications in depression, anxiety, PTSD, and localized pain, subject to ongoing results and regulatory feedback.
“We are pleased to see our Phase 1 program progress as planned,” said Erez Aminov, CEO of MIRA. “Advancing into the MAD stage is an important operational step as we continue to build a rigorous safety and PK foundation for Ketamir-2 and work to deliver a differentiated, non-opioid option for patients with neuropathic pain.“
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
NEW YORK, NY – essoc, a company renowned for its innovative approach to solving the universal and persistent problem of slipping no-show socks, has been officially voted the provider of the best no show socks in a comprehensive consumer poll and industry analysis. This significant accolade reflects the brand’s unwavering commitment to superior comfort, breakthrough innovation, and genuine inclusivity, setting a new and formidable standard in the everyday essentials market. The recognition validates essoc’s success in creating a product that consumers don’t just wear, but genuinely rely on.
The inspiration behind essoc is drawn directly from the dynamic, stylish, and demanding lifestyle of its New York City home. The founder observed a fundamental disconnect: people invested in high-quality footwear for their fast-paced lives, only to be undermined by the constant distraction and discomfort of socks slipping down inside their shoes. This insight sparked a mission to engineer a solution. essoc designed socks that not only stay perfectly in place from the morning commute to a late-night social engagement but also feel like a seamless second skin. This unique and powerful combination of absolute functionality and sublime comfort has resonated deeply with consumers globally, leading directly to the brand earning this prestigious recognition.
“Being recognized as the maker of the best no show socks is a profound testament to our team’s relentless dedication to quality and our core principle of listening intently to our customers’ needs,” said Stella Liu, founder of essoc. “Our mission was never just about making another sock. It was about meticulously re-engineering a fundamental wardrobe item to enhance everyday life, removing a small but significant friction point. This award is incredible validation that our efforts have made a real difference in the daily experience of our customers.”
What truly distinguishes essoc in a crowded marketplace is its holistic approach to design. essoc has a design patent, which mainly protects their cutting technology and overall design.The company invested heavily in research and development, focusing on three key areas: a proprietary, skin-friendly silicone grip technology that provides a secure hold without irritation; an ergonomic, contoured fit that respects the natural shape of the human foot; and the use of premium, breathable fabric blends that ensure all-day freshness and prevent overheating. This trifecta of innovation directly addresses the primary complaints associated with conventional no-show socks—slipping, discomfort, and lack of durability.
“Our socks are more than just a fashion accessory; they are a daily essential engineered to support and empower an active, modern lifestyle,” added Liu. “Whether you’re an executive running between meetings, a creative professional on your feet all day, or a parent navigating the city, your focus should be on your life, not on your socks. We are thrilled to be acknowledged for our commitment to this level of excellence and innovation, proving that even the most basic items can be perfected.”
essoc’s success is deeply rooted in its ability to masterfully blend high-fashion sensibility with uncompromising practicality. The brand offers a product that flawlessly meets the sophisticated demands of modern living, ensuring that individuals never have to sacrifice style for comfort, or function for form. This unwavering focus on creating socks that provide uninterrupted, all-day comfort has allowed essoc to carve out a leadership position. The brand has demonstrated that consumers are eager to invest in high-quality essentials when they deliver tangible benefits and superior performance.
As essoc continues to grow and innovate, this recognition as the best no show socks provider serves as a pivotal milestone. It marks a key moment in its journey to redefine what consumers can and should expect from their everyday apparel. Looking ahead, the brand remains passionately committed to pushing the boundaries of design and functionality, with plans to expand its range of materials and styles. essoc is dedicated to ensuring that its products not only remain at the forefront of the industry but continue to offer the perfect foundation for a confident and comfortable day.
About essoc: essoc was created to solve a small but universal problem—no-show socks that slip off. Inspired by the active, stylish lifestyle of New York City, they designed socks that stay put, feel like a second skin, and keep feet comfortable all day. With a focus on comfort, innovation, and inclusivity, essoc is more than just a sock—it’s a daily essential made for real life. Stay focused. Stay comfortable. Stay put.
Harmony & Healing has announced the launch of its new Private Benefit Concert program, bringing the energy and connection of live music directly into backyards, wineries, corporate spaces, and private event venues. These intimate, high-energy concert/dance parties not only create unforgettable evenings for hosts and their guests, they also raise vital funds to provide free live musical visits to patients in hospitals, hospices, rehab facilities, and memory care centers.
The Private Benefit Concert program offers hosts a turnkey way to throw an extraordinary party with a purpose. Harmony & Healing founder David Victor, a former member of the multi-platinum band BOSTON, performs alongside drummer Michael Brandon and bassist Russell Vazquez in their powerhouse trio, “Therapy Dawgs”. The band delivers multiple sets of crowd-pleasing, danceable hits, transforming private venues into unforgettable live music experiences.
Unlike large, formal benefit concerts that require complex logistics, these events are designed to be simpler for the host. Harmony & Healing handles the performance, lighting, sound, and crew, while the host focuses on food and beverages and inviting friends, family, and colleagues to enjoy the show. These events also feature a lively live auction, with prizes such as autographed guitars, exclusive wine tastings, vacation getaways, and VIP tickets to major sporting events or concerts.
Early hosts are already sharing glowing reviews. Joe Schembri, who hosted a Private Benefit Concert in Danville in June 2025, said, “The energy was absolutely incredible. David and his band brought such professionalism and heart to our backyard. Our guests are still talking about it months later.” In August 2025, Pleasanton host Geoff Rodgers added, “I was worried about logistics, but the team made it so easy. We raised significant funds while creating memories that will last a lifetime.”
The concept works because it creates an exclusive, intimate atmosphere that cannot be replicated in larger venues. Guests enjoy the rare experience of a private concert by professional musicians in a relaxed, familiar setting, while knowing that their participation is helping to fund a meaningful cause. Every dollar raised supports Harmony & Healing’s mission to provide no-cost, live musical visits both in-person and via Zoom to patients of all ages and their loved ones.
Founded by David Victor in the San Francisco Bay Area, Harmony & Healing has become known for its compassionate approach to using music as a tool for emotional connection, stress reduction, and joy. These musical visits are not formal music therapy, but rather carefully curated performances that tap into patients’ most cherished memories and associations. The organization’s professional musicians are selected not only for their talent but for their ability to connect on a personal level with patients, families, and caregivers.
Private Benefit Concerts are an extension of that mission, allowing supporters to bring the same level of artistry and connection into their own communities while raising the funds that make the free patient visits possible. The money generated from each concert directly supports the organization’s roster of artists, ensuring that patients and their families never pay for the performances they receive.
The need for this work is ongoing. Patients in hospitals, hospices, and long-term care facilities often face long days filled with medical procedures and uncertainty. For many, a live musical visit is a welcome break that lifts spirits, rekindles happy memories, and provides moments of genuine human connection. These visits also reach veterans living with PTSD, children in pediatric care, and individuals in memory care, where music can stimulate recognition and response even when other forms of communication have faded.
Victor sees the Private Benefit Concert program as a way to deepen community engagement while sustaining the charity’s impact year-round. “A Private Benefit Concert is more than just a party,” he explained. “It’s a way to connect with your friends and neighbors through great music, while knowing that the joy you experience that night is directly bringing comfort and healing to patients in hospice, rehab and hospitals who truly need it.”
Harmony & Healing encourages interested hosts to think creatively about their venues. While many concerts take place in spacious backyards, others are held in wineries, community centers, or corporate settings. The key is creating a welcoming space where guests can relax, enjoy the music, and participate in the fundraising activities.
The organization provides guidance on event flow, auction timing, and promotion to make each concert as successful as possible. From the moment the band arrives for setup to the final encore, hosts can relax knowing the details are handled. The result is an evening that strengthens community bonds, celebrates live music, and funds a mission that touches lives across the country.
SAN BERNARDINO, CA / ACCESS Newswire / August 19, 2025 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF) (Dateline or the Company), a North American-focused mining and exploration company, is pleased to announce that the integration of a recently completed 3D magneto-telluric (MT) geophysical survey with detailed gravity data has led to the identification of six new high-priority breccia pipe targets at the 100%-owned Colosseum Gold-Rare Earth Element (REE) Project in California.
These targets exhibit the same coincident geophysical anomalies, gravity (density) lows and resistivity lows, observed in the known gold-bearing breccia pipes at Colosseum, significantly expanding the project’s exploration potential and opportunity to grow the existing Mineral Resource Estimate (MRE).
Highlights
Multiple New Targets: Six newly delineated geophysical anomalies share the same signature, coincident gravity-low and low-resistivity, as the breccia pipes hosting the existing 1.1-million-ounce gold mineral resource. This indicates the potential for new gold-bearing breccia pipe structures outside previously drilled or mined areas.
Proven Target Signature: The two known Colosseum breccia pipes are defined by a confluence of key geophysical markers: gravity (density) low and MT resistivity low anomalies. The six new targets exhibit this identical geophysical signature, reinforcing their prospectivity.
1.4-Million Ounces of Gold: Over 1.4Moz of gold has been defined in the two known breccia pipes to ~250 metres depth, comprising a 1.1Moz JORC 2012-compliant mineral resource and ~344koz historically produced.
Large-Scale Anomalies: Four of the six new anomalies are comparable in scale or larger than those associated with the known breccia pipes that host the current MRE, highlighting exploration upside.
Depth Potential: 3D MT results indicate the known breccia pipe structures extend to at least ~300 metres below prior drilling, suggesting the defined gold system may continue well beyond the existing mineral resource shell.
Next Steps – Geochemistry and Drilling: The parallel 3D inversion using the open-source ModEM software and the final geochemistry results will be incorporated into drill planning, with breccia pipe targets to be systematically tested in parallel with ongoing REE exploration activities.
Dateline’s Managing Director, Stephen Baghdadi, commented:
“The MT survey has correlated strongly with the existing 1.1Moz Mineral Resource Estimate, building on the systematic work of recent months. In June, we re-examined the 2023 gravity data alongside new geochemical results from felsite outcrops, confirming that the breccia pipes sit within gravity lows and that felsite dykes carrying gold-pathfinder elements are also coincident with gravity lows on the western margin of the pits.
“This convergence of geochemistry, gravity and MT resistivity data has given us confidence in six new priority targets within 1.5km of the Colosseum mineral resource, four of which are comparable in size or larger than the signatures of the known pipes that have already yielded over 1.4Moz from just the top 250m. The MT model also shows that the known pipes extend at least another 300m below current drilling, reinforcing our view that Colosseum may represent a much larger mineralized system than previously recognized.
“With two drill rigs already on site, we will commence systematic testing of the new targets from September, drilling the highest-priority anomalies while also extending the known pipes at depth. This dual focus positions us to continue growing the gold endowment at Colosseum while advancing our rare earth exploration in parallel. The integration of multiple datasets has both confirmed the robustness of the existing mineral resource and significantly expanded the scale of the opportunity ahead.”
MT Survey Correlates with Known Gold Mineral Resources
A key measure of the MT survey’s effectiveness for gold exploration at Colosseum is whether the existing gold resources produce a discernible geophysical anomaly. A 3D MT inversion model cross-section through the current Mineral Resource demonstrates a strong correlation between low-resistivity anomalies and the mineralized breccia pipes. The geometry of the known pipes closely aligns with both this MT resistivity response and an associated gravity low (low-density zone) evident in the cross-section, confirming the expected breccia pipe geophysical signature. Importantly, the MT inversion also shows that the known breccia pipes remain open at depth for at least an additional ~300 metres below the deepest historical drilling.
Figure 1: 3D resistivity model overlain with the current MRE block model and proposed pit outlines along cross section D-D’ (refer Figure 2). The low resistivity anomalies (purple) show excellent correlation with the known mineral resources.
Six New Gold Targets Defined Within 1.5km of Existing MRE
In June, the Company announced the results of re-examining the gravity survey data from Colosseum, with a potential cluster of breccia pipes identified. The Company’s geophysical consultants completed the 3D MT inversion and then integrated (layered) the results with the gravity and mapping datasets to produce a revised updated set of gold targets for Colosseum.
Six high priority breccia pipe targets have been identified. Four of the six gold targets have dimensions that are comparable or larger in area than the response to the existing mineral resource. Each of the target areas is described in more detail below.
Figure 2: Depth slice at 200m below topography through the 3D density model (left) and resistivity model (right). The new priority targets are labelled 1 to 6 and the positions of the cross sections are also shown.
In Figure 2, lower density (dark blue) and low resistivity (purple) areas are interpreted to identify alluvial fill, alteration, and brecciation of host lithologies. Higher density (red) and high resistivity (blue-white) areas are interpreted to be Early Proterozoic granites possibly including fenitisation and/or carbonatite.
The black triangles denote the new target areas based on this data. The location designated is at the centre of a more extensive geophysical response suggesting considerable extent to the targets. The data also suggests the known mineralization may extend to the northeast. Black outlines are the pit boundaries and black lines are section locations.
Consistent Signature Validates Exploration Model
This consistency in geophysical response between the known and new targets boosts confidence that the anomalies represent the same style of mineralization as the existing Colosseum breccia pipes. While drilling will ultimately determine the nature of each anomaly, the alignment of the key indicators, gravity/density lows and resistivity lows, means the new targets are considered geologically analogous to the proven orebodies. This association obviously increases the probability of exploration success. The Company is encouraged that its work is translating directly into high-quality targets with strong potential to add to the project’s gold inventory.
Figure 3: Top cross section shows a gravity low anomaly that correlates with the 1.4Moz Au (1.1Moz MRE & 344koz Au produced) within the upper 250m vertically. The bottom cross section shows the resistivity low anomaly from the MT survey. Both sections indicate potential for at least 300m vertically below the mineral resource model.
Breccia Pipes Extend to Greater Depths
The MT resistivity inversion also reveals that the low-resistivity anomalies associated with the North and South breccia pipes persist to at least ~300 metres below the deepest historical drilling and mining (~250 m depth). This finding is particularly significant given the scale of the known Colosseum gold system: roughly 1.4 million ounces of gold have been defined within the upper ~250m of these two breccia pipes.
By demonstrating that the breccia pipes likely continue for hundreds of metres past the extent of current drilling, the geophysical data highlight a substantial opportunity for additional gold mineralization below the defined mineral resource. If the grade profile and breccia architecture persist with depth, even a modest vertical extension of the known pipes could translate into a major increase in contained ounces. This depth potential adds a new dimension of upside at Colosseum, beyond the discovery of the new breccia pipe targets.
New Target Descriptions
Following is a summary of the six newly defined gold targets at Colosseum. Further supporting images are presented in Appendix 1.
Target 1: Approximately 250 m by 250 m in area (800 feet by 800 feet), Target 1 is located west of the South Pit. The target area is characterized by a coincident gravity low and low-resistivity anomaly and the geology in this area is interpreted to be dominated by felsite intrusive rocks.
Targets 2 and 3: Located directly to the east of the North Pit, Targets 2 and 3 cover a combined area of roughly 400 m by 300 m (1,300 feet by 1,000 feet). They appear as distinct gravity low anomalies that occur over a shared zone of extremely low resistivity, possibly indicating the two targets are connected at depth. The MT resistivity response associated with Targets 2 and 3 is the most pronounced (lowest resistivity) recorded in the survey area.
Figure 4: Cross section through Targets 1, 2 and 3 showing the gravity low (blue) anomaly in the upper image and the resistivity low (purple) anomaly in the lower image. The existing MRE is also shown with its corresponding gravity/ MT coincident anomalies.
Target 4: An elongate, northwest-aligned anomaly (~400 m by 300 m) south of the South Pit. Target 4 exhibits a coincident gravity low and low-resistivity signature that is strongest near surface, though its geophysical expression extends to only around ~200 m depth. This could represent a shallower breccia pipe-style target that may be easier to explore and potentially mine.
Target 5: One of the largest target areas, Target 5 spans roughly 500 m by 300 m (1,650 feet by 1,000 feet). It is marked by the most extensive low-resistivity anomaly identified in the survey, continuing to the maximum modelled depth of ~900 m (3,000 feet) vertically. This deep conductive zone is accompanied by a broad gravity low anomaly, reinforcing Target 5 as a compelling drill target with significant vertical extent.
Figure 5: Cross section through Targets 4 and 5, showing distinct low gravity anomalies in the upper image and a large low resistivity anomaly in the lower image.
The extent of the depth extent of Target 5 can be seen in Figure 6, which shows a 3D representation of the anomaly along with the B-B’ section line shown in Figure 2.
Figure 6: 3D view of the resistivity anomalies draped over the topography of the area, with Target 5 shown as a large resistivity anomaly of significant depth extent.
Target 6: The final target is a distinct “bullseye” anomaly about 300 m by 300 m (1,000 feet by 1,000 feet) in size, with a coincident gravity low at surface and an underlying MT anomaly (low resistivity). Both the gravity and resistivity anomalies for Target 6 show excellent continuity to ~700 m (2,300 feet) depth, indicating considerable vertical potential, as can be seen in Figure 7.
Figure 7: Cross section through Target 6, showing distinct gravity low anomaly in the upper image and a large resistivity low anomaly in the lower image.
Next Steps: Drill Program Expansion
Dateline is incorporating the breccia pipe targets into its exploration plans. The upcoming drilling program for Colosseum, which was initially being designed to test high-priority REE anomalies, is now being expanded to also include dedicated gold-focused drillholes. Priority drill targets will include several of the largest new breccia pipe anomalies identified by the MT/gravity integration, as well as depth extension holes into the known pipes to probe the continuation of high-grade mineralization below current workings. A parallel 3D inversion model using the open-source ModEM software is expected in the next two weeks and will also be built into the overall targeting model.
The drill program details (including target prioritization, number of holes, and anticipated depths) are being finalized. By running the gold and rare earth exploration efforts in parallel, the Company aims to unlock the dual potential of the Colosseum Project in a co-ordinated manner. Further updates on commencement of drilling and any additional results (such as pending geochemical analyses) will be provided in due course.
Dateline remains confident that this systematic, data-driven exploration approach will continue to yield positive results and create value at Colosseum.
About Dateline Resources Limited
Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF) is an Australian publicly listed company focused on high-value mining and exploration in North America. Its flagship Colosseum Gold-REE Project in California’s Walker Lane Trend combines a proven gold resource with emerging rare earth potential, positioning Dateline as a leader in critical minerals and precious metals.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of applicable securities laws. These statements relate to future events or performance, including the potential of the Colosseum Project, the benefits of U.S. government support, the company’s plans for future development, and the strategic importance of the project for U.S. critical minerals supply. Forward-looking statements are based on current expectations, estimates, and projections and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include fluctuations in gold and rare earth element prices, changes in regulatory or permitting processes, geological or technical challenges, market conditions affecting capital raising, environmental or social factors, and risks related to securing government funding. Dateline Resources cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update or revise these statements, except as required by law.
ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, will host an exclusive live investor webinar with Lantern Pharma Inc. (NASDAQ:LTRN) on August 26, 2025, at 4:15 p.m. ET.
The webinar will showcase how Lantern is redefining the future of cancer drug discovery and development through its proprietary AI and machine learning platform, RADR®, which analyzes more than 200 billion oncology data points and leverages 200+ advanced ML algorithms to compress early drug development timelines by up to 70% and reduce costs by 80%.
During the webinar, Panna Sharma, CEO of Lantern Pharma, will spotlight the company’s advancing clinical pipeline, including:
LP-300: Phase 2 Harmonic™ trial in never-smokers with NSCLC, a $4B+ global market with urgent unmet need.
LP-184: A Phase 1 “blockbuster potential” therapy for DDR-deficient solid tumors, addressing a $10B+ market.
LP-284: A first-in-class drug candidate for aggressive lymphomas, including mantle cell lymphoma and high-grade B-cell lymphoma, with $3.75-4B market potential.
With 11 FDA designations, an expanding ADC program, collaborations with world-class cancer centers (including Johns Hopkins and MD Anderson), and a growing patent estate of 100+ issued and pending patents, Lantern is emerging as a leading global AI drug discovery company.
A live Q&A session with management will follow the presentation.
Questions can be pre-submitted to LTRN@redchip.com or online during the live event.
About Lantern Pharma
Lantern Pharma (NASDAQ:LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 – 2.5 million per program.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip’s products and services, please visit:
HOUSTON, TX / ACCESS Newswire / August 19, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is independent upstream energy company with 20,000 leasehold acres comprised of two fields in the Permian Basin in southeast New Mexico. The fields have a total of 750 producing and injection wells producing over 1,000 barrels of oil per day. Today, the Company reports revenue and earnings for the second quarter of 2025.
Positioned to Retire Senior Debt and Seller Settlement: Favorable funding arrangements expected to close in September creating $40 million in shareholder value.
The Company entered into an agreement (as amended, the “Seller Agreement”) with Pogo Royalty, LLC (“Seller”), which, when closed, will result in: (i) the restructure of the Company’s balance sheet, eliminating approximately $40 million in debt and obligations, and (ii) the purchase of a 10% Overriding Royalty Interest in all of the Company’s oil and gas properties in the Grayburg-Jackson Field. The closing is expected to occur in September 2025 and consideration to Seller is agreed to be $20.5 million in cash and the issuance of 1.5 million shares of the Company’s Class A common stock. The summary of the Agreement with Seller can be found in the Press Release on the Seller Agreement as Amended on the Company’s website.
EON signed an expanded non-binding Letter of Intent (“LOI”) with Enstream Capital Management, LLC (“Enstream”) concerning a volumetric funding arrangement (“VMA”) and revenue sharing for $52.8 million. EON expects to use the funds for the consideration to Seller under the Seller Agreement, as well as for field development and retirement of senior debt. A summary of the Enstream LOI Press Release is available on the Company’s website. We expect to close this transaction in September 2025.
Advancing Horizontal Drilling Program: EON expects to drill up to 90 wells over a three to four year program potentially increasing reserves by up to $100 million in value.
As announced in its Horizontal Drilling Program Press Release, the Company conducted a study for horizontal drilling in the lower intervals of the San Andres formation on the Company’s Grayburg-Jackson Field (“GJF”) which could yield up to 20 million untapped barrels of oil. The study has identified 50 well locations to be drilled over several years, commencing in Q1 of 2026. Each well will cost approximately $3.7 million to drill and is expected to produce 300 to 400 barrels of oil per day (“BOPD”). The Company is actively in discussions with potential drilling partners to share in the working interest ownership, costs and related revenue.
Acquired South Justis Field in June: Adds over 100 BOPD with potential of an additional 250 BOPD over the next year.
On June 20, 2025, EON acquired the South Justis Field (“SJF”) for 1.0 million Class A common shares of the Company without any cash consideration or debt. The Company will have a 94% working interest in the SJF. With the estimated $1.2 million in net annual cash flow, the transaction is expected to be accretive. The SJF comprises 5,360 contiguous acres with 208 combined producing and injection wells with well spacing of 50 acres. The field is located in the Central Basin of the prolific Permian Basin in Lea County, New Mexico. The producing formations include the Glorietta, Blinebry, Tubb, Drinkard and Fusselman intervals, which range from 5,000 feet to 7,000 feet in depth. The original-oil-in-place (“OOIP”) is approximately 207 million barrels of oil. For more details on the acquisition, see the Press Release on the SJF Acquisition, the SJF Investor Call Deck and the SJF Operations Web Page on the Company’s website.
Grayburg-Jackson Field Positioned to Expand Seven Rivers Zone Production: The infrastructure enhancements are nearing completion and three well service rigs are on-site to return idle wells to production and prepare for well recompletions.
Production improvement efforts include: enhanced acid formula treatments on 13 wells has resulted in an increase of 40 BOPD; well servicing work has returned 27 wells to production; and deploying a third well service rig to the field in July to return producing and injection wells to production.
The focus on the GJF over the past year has resulted in infrastructure enhancements nearing completion and stabilizing production. The Company’s engineers have been using technology and science to analyze well logs and prior results in an effort to increase production and identification of the best pay in the Seven Rivers formation. The Company’s team has also rolled out the use of an AI application for our well pumpers to improve efficiencies as described in the AI Implementation Press Release on the Company’s website.
Financial highlights for the quarter ended June 30, 2025:
Revenue
Total revenue for the quarter was $4.6 million. Little changed from Q1 of 2025 and revenue was up approximately $850K from Q4 of 2024.
As discussed in the July 24, 2025 Press Release regarding preliminary results for Q2 of 2025, oil revenue from production was temporarily impacted in Q2 2025. The impact was mitigated by the Company’s hedging position. The Company recovered approximately $290K of cash, as approximately 75% of the oil was hedged at $70.00 per barrel. The non-cash hedge portion had a positive revenue impact of approximately $500K.
Our current oil production is 70%-plus hedged at a price of $70.00 per barrel or greater through the end of CY 2025.
Field results
The Company had income from operations of $1.1 million for the quarter.
The lease operating expenses (“LOE”) dropped to $665K per month for the quarter from the $718K per month for the fiscal year 2024.
Capital expenditure for the second quarter was $730K.
General and administrative (“G&A”) costs
The overall G&A costs were an average of $670K per month for the first six months of 2025; this is down from an average of $865 per month for the fiscal year 2024.
Salaries, fees and related costs for the first two quarters of 2025 are approximately $300K per quarter lower as compared to fiscal 2024.
Professional fees for legal, audit and consulting services for the second quarter of 2025 are $300K lower than the fourth quarter of 2024. These costs are primarily incurred for reporting requirements, financing efforts and certain costs stemming from various trailing legal matters.
Other income and expenses
Interest expense of approximately $1.68 million in Q2 of 2025 is $ approximately 65K lower than Q1 of 2025 due to note conversions; this is on account of our efforts to clean-up the balance sheet and the reduction of the principal balance of the Company’s senior reserve-based loan.
The approximately net $190K of income for non-cash impacts primarily include approximately $332K for the amortization of financing costs, and approximately $207K gain from settling the warrants for the convertible notes.
“During the quarter, we continued to execute on our operational strategy in the Permian Basin while navigating commodity price volatility,” said Dante Caravaggio, President and CEO, EON. “Our focus remains on cost discipline, increasing production levels, and leveraging our hedge positions to manage risk, as well as integrating our acquisition of the South Justis Field.”
“On the Grayburg-Jackson Field, we continued our program in the second quarter to perform larger acid treatment using proprietary chemicals to clean up wellbore damage and increase long-term production” said Jesse Allen, Vice President of Operations, EON. “The result to date is an overall sustained production increase of 40 BOPD from 13 wells. These early results indicate we are undertaking the proper development to enhance our long-term production growth. The Company also contracted a second oil rig in June to help stabilize and increase production, and we expect to continue this program through August 2025 and complete down-hole failure repairs on 41 additional wells.”
“Regarding the recent acquisition of the South Justis Field, when we purchased the field, the production was approximately 108 barrels of oil per day,” Mr. Allen added. “Due to safety concerns we reduced production to 88 barrels of oil per day, but this has been remedied and we are now producing 120 barrels of oil. We have a well service rig at the field to re-activate wells, and we expect production at the South Justis Field to continue to increase.”
August 19, 2025 earnings call information
EON will host a conference call on Tuesday, August 19, 2025, at 2:30 p.m. Eastern Time to review its second quarter 2025 financial results. Dante Caravaggio will chair the call; Mitchell B. Trotter Jesse Allen will also speak with shareholders and answer questions.
To listen to a live broadcast: An audio Webcast of the conference call will be available within two hours of the call on August 19, 2025. To listen to a live broadcast, visit the website at least 15 minutes prior to the scheduled start to register and download and install any necessary software.
Earnings Call deck: The earnings call deck will be posted to the Company’s website prior to the earnings call.
Teleconference Replay Number (Expires September 2, 2025):
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 52885
About EON Resources Inc.
EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. EON’s long-term goal is to maximize total shareholder value from a diversified portfolio of long-life oil and natural gas properties built through acquisition and through selective development, production enhancement and other exploitation efforts on its oil and natural gas properties.
EON’s Class A Common Stock trades on the NYSE American Stock Exchange (NYSE American:EONR) and the Company’s public warrants trade on the NYSE American Stock Exchange (NYSE American:EONR WS). For more information on EON, please visit the Company’s website: https://eon-r.com/.
About the Grayburg-Jackson Oil Field Property
LH Operating, LLC (“LHO”), a wholly owned subsidiary of EON, operates its holdings in New Mexico of oil and gas waterflood production comprising 13,700 contiguous leasehold acres, 342 producing wells and 207 injection wells situated on 20 federal and 3 state leases in the Grayburg-Jackson Oil Field. The Grayburg-Jackson Oil Field is located on the Northwest Shelf of the prolific Permian Basin in Eddy County, New Mexico.
Leasehold rights of LHO include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2024 reserve report from our third-party engineer, Haas and Cobb Petroleum Consultants, LLC (“Haas & Cobb” or “Cobb”), reflects LHO to have proven reserves of approximately 14.0 million barrels of oil and 2.8 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) in the LHO leasehold is approximately 876 million barrels of oil in the Grayburg and San Andres intervals and 80 million barrels in the Seven Rivers interval for a total OOIP of approximately 956 million barrels of oil.
Our primary production is currently from the Seven Rivers zone. In addition to proven reserves, the Company believes it may access an additional 34 million barrels of oil by adding perforations in the Grayburg and San Andres formations, plus another 40 million barrels from the horizontal drilling program in the San Andres. With proven oil reserves of over 15 million barrels, combined with the potential 74 million additional barrels from the Grayburg and San Andres zones, LHO should produce oil and a revenue stream for more than two decades with a low decline rate.
About the South Justis Field Property
The South Justis Field (“SJF”) is a carbonate reservoir, similar to the rest of the Permian. The SJF was first developed in the 1960’s and had an initial production in the 6,000 BOPD range. The waterflood implemented at a cost of $40 million dollars in the 1990’s by a major oil company had mediocre performance due to poor connectivity between wells, which indicates an opportunity for horizontal infill well drilling. The subsequent owners of the SJF had higher priorities, which led to an increase in idle wells with downhole failures, thus allowing the production to drop dramatically. The Seller acquired the field and has reactivated several wells with good results increasing the production of oil. This indicates that there are a significant number of wells that can be reactivated to increase production on existing wells.
The SJF comprises of 5,360 contiguous acres with 208 combined producing and injection wells with well spacing of 50 acres. The field is located in the Central Basin of the prolific Permian Basin in Lea County, New Mexico located approximately 100 miles from EON’s Grayburg-Jackson Oil Field property. The producing formations include the Glorietta, Blinebry, Tubb, Drinkard and Fusselman intervals that range from 5,000 feet to 7,000 feet in depth. The original-oil-in-place (“OOIP”) is approximately 207 million barrels of oil.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Investor Relations Michael J. Porter, President PORTER, LEVAY & ROSE, INC. mike@plrinvest.com
